20 May 2004
Coagulation inhibitors – antithrombin and protein C and periventricular leukomalacia in premature infants
Iwona Sadowska-Krawczenko, Małgorzata Ćwiklińska-Jurkowska, Piotr Korbal, Wiesław SzymańskiMed Sci Monit 2004; 10(2): 88-91 :: ID: 11852
Abstract
Background: Despite the great progress in neonatology since the 1990s, brain injury and neurodevelopmental impairment in the newborns remain common. Cranial imaging and neuropathology data indicate that periventricular leukomalacia can coexist with periventricular-intraventricular haemorrhage but they also may have separate pathogenic mechanisms. PVL refers to necrosis of the periventricular matter adjacent to the external angles of the lateral ventricles. The pathogenesis of this lesion relates to three major interacting factors: an incomplete state of development of the vascular supply to the cerebral white matter, a maturation-dependent impairment in regulation of cerebral blood flow and the maturation-dependent vulnerability of the oligodendroglial (OL) precursor cell that represents the major cellular target in PVL. The purpose of our study was to evaluate possible correlation between coagulation inhibitors and periventricular leukomalacia. Material/Methods: Serum samples were tested from 189 premature infants 20–30 minutes after delivery and on the 3rd day of life. Following laboratory tests were performed: C- reactive protein (12 hours after delivery), blood gases, blood cell count with smear, antithrombin activity, protein C activity, electrolytes. Arterial blood pressure was also measured.Results: 19 of 189 newborns were diagnosed with PVL according to cranial ultrasonography and neurological examination performed at the age of 2 months. In the group of children with PVL we have found lower activity of antithrombin and protein C in comparison to children without PVL.Conclusions: Etiology of periventricular leukomalacia is multifactorial and we conclude that activation of coagulation may have a significant effect on the patophysiology of this complication.
Keywords: antithrombin, periventricular leukomalacia, Protein C
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952